Spruce Biosciences, Inc.
General ticker "SPRB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $9.7M (TTM average)
Spruce Biosciences, Inc. follows the US Stock Market performance with the rate: 26.4%.
Estimated limits based on current volatility of 7.8%: low 82.35$, high 96.34$
Factors to consider:
- Total employees count: 29 (+7.4%) as of 2023
- Top business risk factors: Limited operating history, Speculative nature of biopharma investments, Economic downturns and volatility, Market competition, Liquidity and credit risks
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [84.04$, 256.45$]
- 2024-12-30 to 2025-12-30 estimated range: [53.60$, 173.67$]
Financial Metrics affecting the SPRB estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3064.50 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 73.60 > 63.39
- Negative: Industry earnings per price (median), % of -22.08 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term SPRB quotes
Long-term SPRB plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $10.09MM |
| Operating Expenses | $42.07MM | $47.28MM | $62.08MM |
| Operating Income | $-42.07MM | $-47.28MM | $-51.99MM |
| Non-Operating Income | $-0.23MM | $1.10MM | $4.07MM |
| Interest Expense | $0.34MM | $0.42MM | $0.48MM |
| R&D Expense | $30.70MM | $35.20MM | $49.43MM |
| Income(Loss) | $-42.29MM | $-46.18MM | $-47.92MM |
| Profit(Loss)* | $-42.29MM | $-46.18MM | $-47.92MM |
| Stockholders Equity | $111.37MM | $68.49MM | $76.51MM |
| Assets | $126.49MM | $85.65MM | $103.95MM |
| Operating Cash Flow | $-35.88MM | $-41.68MM | $-33.27MM |
| Capital expenditure | $0.09MM | $0.01MM | $0.01MM |
| Investing Cash Flow | $-79.17MM | $23.69MM | $55.78MM |
| Financing Cash Flow | $0.64MM | $-0.24MM | $49.14MM |
| Earnings Per Share** | $-69.63 | $-75.49 | $-95.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.